Skip to main content

Sagimet Biosciences Inc

For the period ended Dec 31, 2023. Filed Mar 25, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 25, 2024

SGMT$10.83+9.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.

​SAGIMET BIOSCIENCES, INC.
​​
Date: March 25, 2024By:/s/ David Happel
​​David Happel
​​President and Chief Executive Officer
​​(Principal Executive Officer)
​​​
​​​
Date: March 25, 2024By:/s/ Joseph Oriti
​​Joseph Oriti
​​Interim Principal Financial Officer
​​(Interim Principal Financial and Accounting Officer)
​​​
​​​

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of David Happel and Joseph Oriti his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

​​​​​
Name​Title​Date
​​​​​
/s/ David Happel​President, Chief Executive Officer, and Director​March 25, 2024
David Happel​(Principal Executive Officer)​​
​​​​​
/s/ Joseph Oriti​Interim Principal Financial Officer​March 25, 2024
Joseph Oriti​(Interim Principal Financial and Accounting Officer)​​
​​​​​
/s/ George Kemble, PhD​Executive Charmain of the Board​March 25, 2024
George Kemble, PhD​​​​
​​​​​
/s/ Elizabeth Grammer, Esq.​Director​March 25, 2024
Elizabeth Grammer, Esq.​​​​
​​​​​
/s/ Beth Seidenberg, MD​Director​March 25, 2024
Beth Seidenberg, MD​​​​
​​​​​
/s/ Merdad Parsey, PhD​Director​March 25, 2024
Merdad Parsey, PhD​​​​
​​​​​
/s/ Richard Rogers​Director​March 25, 2024
Richard Rogers​​​​
​​​​​
​​Director​March 25, 2024
Jinzi J. Wu, PhD​​​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.